Cargando…

NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity

BACKGROUND: There is a hypothesis that a sufficient level of endothelial nitric oxide synthase is important for reliable protection against COVID-19. Theoretical ideas about the NOS3 gene demonstrated that it can have an effect on links of the complications pathogenesis in COVID-associated pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishchuk, Liliia, Rossokha, Zoia, Pokhylko, Valeriy, Cherniavska, Yuliia, Dubitska, Olha, Vershyhora, Viktoriia, Tsvirenko, Svitlana, Kovtun, Serhii, Gorovenko, Nataliia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082643/
https://www.ncbi.nlm.nih.gov/pubmed/37037281
http://dx.doi.org/10.1016/j.niox.2023.04.002
_version_ 1785021354750246912
author Fishchuk, Liliia
Rossokha, Zoia
Pokhylko, Valeriy
Cherniavska, Yuliia
Dubitska, Olha
Vershyhora, Viktoriia
Tsvirenko, Svitlana
Kovtun, Serhii
Gorovenko, Nataliia
author_facet Fishchuk, Liliia
Rossokha, Zoia
Pokhylko, Valeriy
Cherniavska, Yuliia
Dubitska, Olha
Vershyhora, Viktoriia
Tsvirenko, Svitlana
Kovtun, Serhii
Gorovenko, Nataliia
author_sort Fishchuk, Liliia
collection PubMed
description BACKGROUND: There is a hypothesis that a sufficient level of endothelial nitric oxide synthase is important for reliable protection against COVID-19. Theoretical ideas about the NOS3 gene demonstrated that it can have an effect on links of the complications pathogenesis in COVID-associated pneumonia. We determined the goal – to investigate the association of the NOS3 gene variants with the occurrence of the disease and its clinical course in patients of the intensive care unit. METHODS: The study group included 117 patients with a diagnosis of severe “viral COVID-19 pneumonia”. Determination of NOS3 gene variants was performed using the PCR method. The probability of differences in the quantitative results were determined using ANOVA or Kruskal-Wallis test (depend of normality of studied parameters). RESULTS: Our results indicate that the presence of the NOS3 gene 4a allele increase the risk of complicated COVID-19-associated pneumonia (χ(2) = 18.84, p = 0.00001, OR = 3.53 (1.95–6.39)). It was showed, that carriers of the 4aa genotype had a significantly higher ratio of SpO(2)/FiO(2) on the first and second days after hospitalization (p = 0.017 and p = 0.03, respectively). Patients with the 4aa genotype also had the acid-base imbalances, as showed by indicators of base deficiency and standard bicarbonate, which were beyond the reference values. Potassium and sodium concentrations on the first and second day after hospitalization were also significantly lower in patients with 4aa genotype (p = 0.009 and p = 0.048, respectively), for whom, in the same time, the concentrations of C-reactive protein and total bilirubin were significantly higher (p = 0.002 and p = 0.033, respectively). CONCLUSIONS: Our results confirmed that the rs61722009 variant of the NOS3 gene is associated with an increased risk of severe СOVID-19-associated pneumonia and its adverse clinical course with potential progression of kidney and liver damage, and occurrence risk of systemic inflammatory response syndrome. These results require further research for the new metabolic strategy formation, in order to prevent the severe COVID-19 associated pneumonia and its complications.
format Online
Article
Text
id pubmed-10082643
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100826432023-04-10 NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity Fishchuk, Liliia Rossokha, Zoia Pokhylko, Valeriy Cherniavska, Yuliia Dubitska, Olha Vershyhora, Viktoriia Tsvirenko, Svitlana Kovtun, Serhii Gorovenko, Nataliia Nitric Oxide Article BACKGROUND: There is a hypothesis that a sufficient level of endothelial nitric oxide synthase is important for reliable protection against COVID-19. Theoretical ideas about the NOS3 gene demonstrated that it can have an effect on links of the complications pathogenesis in COVID-associated pneumonia. We determined the goal – to investigate the association of the NOS3 gene variants with the occurrence of the disease and its clinical course in patients of the intensive care unit. METHODS: The study group included 117 patients with a diagnosis of severe “viral COVID-19 pneumonia”. Determination of NOS3 gene variants was performed using the PCR method. The probability of differences in the quantitative results were determined using ANOVA or Kruskal-Wallis test (depend of normality of studied parameters). RESULTS: Our results indicate that the presence of the NOS3 gene 4a allele increase the risk of complicated COVID-19-associated pneumonia (χ(2) = 18.84, p = 0.00001, OR = 3.53 (1.95–6.39)). It was showed, that carriers of the 4aa genotype had a significantly higher ratio of SpO(2)/FiO(2) on the first and second days after hospitalization (p = 0.017 and p = 0.03, respectively). Patients with the 4aa genotype also had the acid-base imbalances, as showed by indicators of base deficiency and standard bicarbonate, which were beyond the reference values. Potassium and sodium concentrations on the first and second day after hospitalization were also significantly lower in patients with 4aa genotype (p = 0.009 and p = 0.048, respectively), for whom, in the same time, the concentrations of C-reactive protein and total bilirubin were significantly higher (p = 0.002 and p = 0.033, respectively). CONCLUSIONS: Our results confirmed that the rs61722009 variant of the NOS3 gene is associated with an increased risk of severe СOVID-19-associated pneumonia and its adverse clinical course with potential progression of kidney and liver damage, and occurrence risk of systemic inflammatory response syndrome. These results require further research for the new metabolic strategy formation, in order to prevent the severe COVID-19 associated pneumonia and its complications. Elsevier Inc. 2023-05-01 2023-04-08 /pmc/articles/PMC10082643/ /pubmed/37037281 http://dx.doi.org/10.1016/j.niox.2023.04.002 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Fishchuk, Liliia
Rossokha, Zoia
Pokhylko, Valeriy
Cherniavska, Yuliia
Dubitska, Olha
Vershyhora, Viktoriia
Tsvirenko, Svitlana
Kovtun, Serhii
Gorovenko, Nataliia
NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity
title NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity
title_full NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity
title_fullStr NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity
title_full_unstemmed NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity
title_short NOS3 (rs61722009) gene variants testing in prediction of COVID-19 pneumonia severity
title_sort nos3 (rs61722009) gene variants testing in prediction of covid-19 pneumonia severity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082643/
https://www.ncbi.nlm.nih.gov/pubmed/37037281
http://dx.doi.org/10.1016/j.niox.2023.04.002
work_keys_str_mv AT fishchukliliia nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT rossokhazoia nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT pokhylkovaleriy nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT cherniavskayuliia nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT dubitskaolha nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT vershyhoraviktoriia nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT tsvirenkosvitlana nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT kovtunserhii nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity
AT gorovenkonataliia nos3rs61722009genevariantstestinginpredictionofcovid19pneumoniaseverity